IN2014MN02418A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MN02418A IN2014MN02418A IN2418MUN2014A IN2014MN02418A IN 2014MN02418 A IN2014MN02418 A IN 2014MN02418A IN 2418MUN2014 A IN2418MUN2014 A IN 2418MUN2014A IN 2014MN02418 A IN2014MN02418 A IN 2014MN02418A
- Authority
- IN
- India
- Prior art keywords
- methods
- breast cancer
- subject
- gene expression
- evaluating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention provides methods for classifying and for evaluating the prognosis of a subject having breast cancer are provided. The methods include prediction of breast cancer subtype using a supervised algorithm trained to stratify subjects on the basis of breast cancer intrinsic subtype. The prediction model is based on the gene expression profile of the intrinsic genes listed in Table 1. Further provided are compositions and methods for predicting outcome or response to therapy of a subject diagnosed with or suspected of having breast cancer. These methods are useful for guiding or determining treatment options for a subject afflicted with breast cancer. Methods of the invention further include means for evaluating gene expression profiles including microarrays and quantitative polymerase chain reaction assays as well as kits comprising reagents for practicing the methods of the invention.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261650209P | 2012-05-22 | 2012-05-22 | |
US201361753673P | 2013-01-17 | 2013-01-17 | |
PCT/US2013/042157 WO2013177245A2 (en) | 2012-05-22 | 2013-05-22 | Nano46 genes and methods to predict breast cancer outcome |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014MN02418A true IN2014MN02418A (en) | 2015-08-14 |
Family
ID=49624503
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN2418MUN2014 IN2014MN02418A (en) | 2012-05-22 | 2013-05-22 |
Country Status (12)
Country | Link |
---|---|
US (3) | US20130337444A1 (en) |
EP (1) | EP2852689B1 (en) |
JP (1) | JP6325530B2 (en) |
CN (2) | CN111500718A (en) |
AU (1) | AU2013266419B2 (en) |
BR (1) | BR112014029300A2 (en) |
CA (1) | CA2874492C (en) |
ES (1) | ES2763931T3 (en) |
IL (1) | IL235795B (en) |
IN (1) | IN2014MN02418A (en) |
MX (1) | MX369628B (en) |
WO (1) | WO2013177245A2 (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009158143A1 (en) | 2008-05-30 | 2009-12-30 | The University Of North Carolina At Chapel Hill | Gene expression profiles to predict breast cancer outcomes |
JP5971769B2 (en) | 2011-03-15 | 2016-08-17 | ザ ユニバーシティー オブ ノースカロライナ アット チャペル ヒル | Methods of treating breast cancer using anthracycline therapy |
GB201106254D0 (en) | 2011-04-13 | 2011-05-25 | Frisen Jonas | Method and product |
EP2785873A4 (en) | 2011-11-30 | 2015-11-11 | Univ North Carolina | Methods of treating breast cancer with taxane therapy |
EP2997163A4 (en) * | 2013-05-13 | 2017-02-22 | Nanostring Technologies, Inc | Methods to predict risk of recurrence in node-positive early breast cancer |
EP3013983B1 (en) | 2013-06-25 | 2023-02-15 | Prognosys Biosciences, Inc. | Spatially encoded biological assays using a microfluidic device |
WO2015035377A1 (en) * | 2013-09-09 | 2015-03-12 | British Columbia Cancer Agency Branch | Methods and kits for predicting outcome and methods and kits for treating breast cancer with radiation therapy |
CN107208144B (en) | 2014-11-21 | 2021-06-08 | 纳米线科技公司 | Enzyme-free and amplification-free sequencing |
US10246700B2 (en) * | 2014-11-24 | 2019-04-02 | Nanostring Technologies, Inc. | Methods and apparatuses for gene purification and imaging |
JP2018500895A (en) * | 2014-12-09 | 2018-01-18 | キングス・カレッジ・ロンドン | Breast cancer treatment with taxane therapy |
SG11201707515SA (en) | 2015-04-10 | 2017-10-30 | Spatial Transcriptomics Ab | Spatially distinguished, multiplex nucleic acid analysis of biological specimens |
US20180209981A1 (en) * | 2015-07-23 | 2018-07-26 | National University Of Singapore | Wbp2 as a co-prognostic factor with her2 for stratification of patients for treatment |
CA3023566A1 (en) | 2016-05-16 | 2017-11-23 | Nanostring Technologies, Inc. | Methods for detecting target nucleic acids in a sample |
US11352667B2 (en) | 2016-06-21 | 2022-06-07 | 10X Genomics, Inc. | Nucleic acid sequencing |
WO2018074865A2 (en) * | 2016-10-21 | 2018-04-26 | 서울대학교병원 | Composition and method for breast cancer prognosis prediction |
CA3043489A1 (en) | 2016-11-21 | 2018-05-24 | Nanostring Technologies, Inc. | Chemical compositions and methods of using same |
KR101950717B1 (en) * | 2016-11-23 | 2019-02-21 | 주식회사 젠큐릭스 | Methods for predicting effectiveness of chemotherapy for breast cancer patients |
US11978535B2 (en) * | 2017-02-01 | 2024-05-07 | The Translational Genomics Research Institute | Methods of detecting somatic and germline variants in impure tumors |
CA3078158A1 (en) | 2017-10-06 | 2019-04-11 | Cartana Ab | Rna templated ligation |
KR102071491B1 (en) * | 2017-11-10 | 2020-01-30 | 주식회사 디시젠 | Breast cancer prognosis prediction method and system based on machine learning using next generation sequencing |
EP3794146A1 (en) | 2018-05-14 | 2021-03-24 | Nanostring Technologies, Inc. | Chemical compositions and methods of using same |
EP3877549A1 (en) * | 2018-11-05 | 2021-09-15 | BioNTech Diagnostics GmbH | Predictive methods in breast cancer |
CA3139791A1 (en) | 2019-05-31 | 2020-12-03 | 10X Genomics, Inc. | Method of detecting target nucleic acid molecules |
JP7352937B2 (en) * | 2019-07-19 | 2023-09-29 | 公立大学法人福島県立医科大学 | Differential marker gene set, method and kit for differentiating or classifying breast cancer subtypes |
EP3945136A1 (en) * | 2020-07-28 | 2022-02-02 | Hospital Clínic de Barcelona | In vitro method for the prognosis of patients suffering from her2-positive breast cancer |
WO2023117807A1 (en) * | 2021-12-20 | 2023-06-29 | Reveal Genomics S.L | Development and validation of an in vitro method for the prognosis of patients suffering from her2-positive breast cancer |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
DE69217497T2 (en) | 1991-09-18 | 1997-06-12 | Affymax Tech Nv | METHOD FOR SYNTHESISING THE DIFFERENT COLLECTIONS OF OLIGOMERS |
US5384261A (en) | 1991-11-22 | 1995-01-24 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis using mechanically directed flow paths |
DE69233501T2 (en) | 1991-11-22 | 2006-02-23 | Affymetrix, Inc. (n.d.Ges.d.Staates Delaware), Santa Clara | Combinatorial strategies for polymer synthesis |
US5856174A (en) | 1995-06-29 | 1999-01-05 | Affymetrix, Inc. | Integrated nucleic acid diagnostic device |
EP0880598A4 (en) | 1996-01-23 | 2005-02-23 | Affymetrix Inc | Nucleic acid analysis techniques |
US6033860A (en) | 1997-10-31 | 2000-03-07 | Affymetrix, Inc. | Expression profiles in adult and fetal organs |
US6020135A (en) | 1998-03-27 | 2000-02-01 | Affymetrix, Inc. | P53-regulated genes |
US6750015B2 (en) * | 2000-06-28 | 2004-06-15 | Kathryn B. Horwitz | Progesterone receptor-regulated gene expression and methods related thereto |
US20020168639A1 (en) * | 2000-09-22 | 2002-11-14 | Muraca Patrick J. | Profile array substrates |
ES2690168T3 (en) | 2003-06-24 | 2018-11-19 | Genomic Health, Inc. | Prediction of the probability of cancer recurrence |
US20050071087A1 (en) * | 2003-09-29 | 2005-03-31 | Anderson Glenda G. | Systems and methods for detecting biological features |
CA2574447A1 (en) | 2004-07-15 | 2006-01-26 | University Of Utah Research Foundation | Housekeeping genes and methods for identifying the same |
CN101061480A (en) * | 2004-09-22 | 2007-10-24 | 三路影像公司 | Methods and computer program products for analysis and optimization of marker candidates for cancer prognosis |
US20090299640A1 (en) | 2005-11-23 | 2009-12-03 | University Of Utah Research Foundation | Methods and Compositions Involving Intrinsic Genes |
ES2374788T3 (en) | 2005-12-23 | 2012-02-22 | Nanostring Technologies, Inc. | NANOINFORMERS AND METHODS FOR PRODUCTION AND USE. |
AU2006330834B2 (en) | 2005-12-23 | 2013-09-12 | Nanostring Technologies, Inc. | Compositions comprising oriented, immobilized macromolecules and methods for their preparation |
CA2687292C (en) | 2007-04-10 | 2017-07-04 | Nanostring Technologies, Inc. | Methods and computer systems for identifying target-specific sequences for use in nanoreporters |
WO2008150512A2 (en) * | 2007-06-04 | 2008-12-11 | University Of Louisville Research Foundation, Inc. | Methods for identifying an increased likelihood of recurrence of breast cancer |
JP2010538609A (en) * | 2007-09-06 | 2010-12-16 | バイオセラノスティクス,インコーポレイティド | Tumor grade classification and cancer prognosis |
WO2009158143A1 (en) | 2008-05-30 | 2009-12-30 | The University Of North Carolina At Chapel Hill | Gene expression profiles to predict breast cancer outcomes |
ES2614810T3 (en) | 2008-08-14 | 2017-06-02 | Nanostring Technologies, Inc | Stable nano-indicators |
MX2012011167A (en) * | 2010-03-31 | 2013-02-07 | Sividon Diagnostics Gmbh | Method for breast cancer recurrence prediction under endocrine treatment. |
-
2013
- 2013-05-22 US US13/899,656 patent/US20130337444A1/en not_active Abandoned
- 2013-05-22 CN CN201911216650.9A patent/CN111500718A/en active Pending
- 2013-05-22 CA CA2874492A patent/CA2874492C/en active Active
- 2013-05-22 EP EP13794236.3A patent/EP2852689B1/en active Active
- 2013-05-22 IN IN2418MUN2014 patent/IN2014MN02418A/en unknown
- 2013-05-22 BR BR112014029300A patent/BR112014029300A2/en not_active Application Discontinuation
- 2013-05-22 AU AU2013266419A patent/AU2013266419B2/en active Active
- 2013-05-22 ES ES13794236T patent/ES2763931T3/en active Active
- 2013-05-22 MX MX2014014275A patent/MX369628B/en active IP Right Grant
- 2013-05-22 JP JP2015514143A patent/JP6325530B2/en active Active
- 2013-05-22 WO PCT/US2013/042157 patent/WO2013177245A2/en active Application Filing
- 2013-05-22 CN CN201380038875.4A patent/CN104704128A/en active Pending
-
2014
- 2014-11-20 IL IL235795A patent/IL235795B/en active IP Right Grant
-
2020
- 2020-02-14 US US16/792,051 patent/US20200332368A1/en not_active Abandoned
-
2022
- 2022-09-29 US US17/936,745 patent/US20230272476A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20200332368A1 (en) | 2020-10-22 |
US20130337444A1 (en) | 2013-12-19 |
EP2852689A4 (en) | 2016-05-11 |
EP2852689B1 (en) | 2019-12-11 |
JP2015518724A (en) | 2015-07-06 |
WO2013177245A3 (en) | 2015-01-29 |
JP6325530B2 (en) | 2018-05-16 |
IL235795A0 (en) | 2015-01-29 |
CA2874492A1 (en) | 2013-11-28 |
EP2852689A2 (en) | 2015-04-01 |
CN111500718A (en) | 2020-08-07 |
AU2013266419A1 (en) | 2014-12-11 |
WO2013177245A2 (en) | 2013-11-28 |
CN104704128A (en) | 2015-06-10 |
MX2014014275A (en) | 2015-07-06 |
AU2013266419B2 (en) | 2018-09-27 |
BR112014029300A2 (en) | 2017-07-25 |
US20230272476A1 (en) | 2023-08-31 |
MX369628B (en) | 2019-11-14 |
CA2874492C (en) | 2021-10-19 |
IL235795B (en) | 2020-02-27 |
ES2763931T3 (en) | 2020-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014MN02418A (en) | ||
CY1114993T1 (en) | Gene Expression Profile To Predict Breast Cancer Outcomes | |
EA201390762A1 (en) | NEW BIOMARKERS TO PREDICT THE OUTCOME OF ANTICATIVE IMMUNOTHERAPY | |
MX2019007814A (en) | Gene expression profile algorithm and test for determining prognosis of prostate cancer. | |
MX2020001156A (en) | Method for the prognosis and treatment of cancer metastasis. | |
NZ599194A (en) | Methods to predict clinical outcome of cancer | |
WO2010051314A3 (en) | Genomic classification of non-small cell lung carcinoma based on patterns of gene copy number alterations | |
MX357429B (en) | Predictors for cancer treatment. | |
PH12014502410A1 (en) | Breast cancer prognosis, prediction of progesterone receptor subtype and|prediction of response to antiprogestin treatment based on gene expression | |
NZ621638A (en) | Dna methylation in colorectal and breast cancer diagnostic methods | |
WO2014184679A3 (en) | Method for the prognosis and treatment of renal cell carcinoma metastasis | |
MX2013008252A (en) | Prognostic signature for colorectal cancer recurrence. | |
BR112015022977A2 (en) | methods for predicting risk of metastasis in cutaneous melanoma | |
Montserrat et al. | Present and future of personalized medicine in CLL | |
RU2010149541A (en) | METHOD FOR FORECASTING THE DEVELOPMENT OF METABOLIC SYNDROME IN A PATIENT WITH ABDOMINAL OBESITY | |
MX2013013153A (en) | Kiaa1456 expression predicts survival in patients with colon cancer. | |
Eapen | Relapsed acute lymphoblastic leukemia: Is it crucial to achieve molecular remission prior to transplant? | |
Cui et al. | DIFFERENTIALLY EXPRESSED MIRNAS AND THEIR SURVIVAL PREDICTION IN THE HIGH GRADE SEROUS AND CLEAR CELL OVARIAN CARCINOMA: IGCS-0043 06. Ovarian Cancer | |
UA108260U (en) | METHOD OF FORECASTING OSTEOPOROSIS DEVELOPMENT | |
WO2011133500A3 (en) | Detection and analysis of epigenetic and genetic changes in tumor tissue | |
UA95616U (en) | METHOD OF FORECASTING FRAGMENT FRAGMENT | |
Salmoiraghi et al. | Next Generation Sequencing (NGS) of TP53 Gene Allows to Identify a Very High Risk Group of Philadelphia Negative Acute Lymphoblastic Leukemia (ALL) Patients | |
Brennan | Quantifying Biomarker Risks and Benefits | |
Gonzalez-Angulo | Putting Genomics into Clinical Practice | |
Ellis | Whole Genome Sequencing for Luminal-Type Breast Cancer |